Financial Highlights

FY ended March 2025

• Overall sales increased 1.5% over the previous fiscal year. In Japan, the Company concentrated on enhancing sales activities which match each market; the acute care hospital market, the small and mid-sized hospital market, and the clinic market. The Company also focused on its consumables and services business as well as strengthening its marketing and service capabilities, creating customer value which contributed to improving medical safety, patient outcomes, and operating efficiency. As a result of these initiatives, domestic sales increased. Internationally, sales increased on a yen basis due to currency effect. Sales on a local currency basis decreased due to lower sales in Asia & Other and Latin America, as well as the impact of a change in the fiscal term of Defibtech, LLC according to the reorganization of subsidiaries in the U.S. in FY2023.
  *In the previous fiscal year, Defibtech, LLC changed its fiscal term from end on December 31 to end on March 31, according to the reorganization of U.S. subsidiaries. In FY2023 ended March 31, 2024, Nihon Kohden consolidated the 15 months of Defibtech’s operating results from January 1, 2023 to March 31, 2024.
• Operating income increased 5.7%, as gross profit margin improved due to decrease in inventory devaluation, higher selling prices, and favorable product mix.
• Ordinary income decreased 20.4%, reflecting foreign exchange losses compared to gains in FY2023.
• Income attributable to owners of parent decreased 17.2%, as gain on sales of investment securities and loss on devaluation of investment securities were recorded as extraordinary income and extraordinary losses, respectively.